2010: Merck commits an estimated $840 million over the next 5 years through their HIV prevention and treatment, childhood asthma programs and donation of HPV vaccine, GARDASIL®, to organizations and institutions in eligible lowest income countries to enable countries to develop capacity to implement vaccination programs. Merck and Qiagen are also committed to increasing access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world through up to five million doses of GARDASIL and HPV DNA tests to screen an additional 500,000 women. The two companies will also support the development and implementation of sustainable best practice models for cervical cancer reduction in low-income, high disease burden countries.

Through Merck's HIV prevention and treatment, childhood asthma programs and donation of HPV vaccine, GARDASIL®, to organizations and institutions in eligible lowest income countries to enable countries to develop capacity to implement vaccination programs. Merck will also partner with Qiagen in increasing access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world.

Qiagen